The U.S. Food and Drug Administration granted an orphan drug designation to Changchun High-Tech Industry's (SHE:000661) unit, Changchun GeneScience Pharmaceutical, for its GenSci128 tablets as a treatment for pancreatic cancer, according to a Wednesday filing on the Shenzhen bourse.
The designation will help facilitate the subsequent development and review of the Chinese drugmaker's drug in the U.S. for the indicated cancer.